SLC34A2

Across TCGA pan-cancer cohorts, SLC34A2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC34A2 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher SLC34A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC34A2 expression acts as an unfavorable survival marker.

THYM, BRCA, and THCA are the cancer types where SLC34A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BRCA	OS	Median	All	0.096	0.579	<.001	18	view →
THCA	DFS	Median	All	0.116	0.916	<.001	16	view →
PRAD	DFS	Median	All	0.143	0.777	<.001	6	view →
LIHC	DFS	Median	All	0.122	0.530	.010	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC34A2–THYM (OS)

Open the THYM breakdown →